4,6-二氯-7-氮杂吲哚 | 5912-18-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 4,6-二氯-7-氮杂吲哚
• 中文别名: 4,6-二氯-1H-吡咯并[2,3-b]吡啶
• 英文名称: 4,6-dichloro-1H-pyrrolo[2,3-b]pyridine
• 英文别名: 4,6-dichloro-7-azaindole
• CAS: 5912-18-5
• 化学式: C₇H₄Cl₂N₂
• mdl: MFCD09880157
• 分子量: 187.028
• InChiKey: LKORXMRYXIGVNO-UHFFFAOYSA-N

物化性质

• 熔点：
  207-208 °C
• 沸点：
  356.7±42.0 °C(Predicted)
• 密度：
  1.61±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存储条件：室温、干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4,6-Dichloro-1h-pyrrolo[2,3-b]pyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4,6-Dichloro-1h-pyrrolo[2,3-b]pyridine
CAS number: 5912-18-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H4Cl2N2
Molecular weight: 187

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4,6-二氯-7-氮杂吲哚 在 sodium hydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 反应 3.0h， 生成 4-[6-Chloro-1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridin-4-yl]oxy-3-fluoroaniline
  参考文献：
  名称：

  有效合成4-O-和C-取代的7-氮杂吲哚

  摘要：

  6-氯-4-硝基-和4,6-二氯-1 H-吡咯并[2,3- b ]吡啶是通用的构建基团，允许通过4的简单亲核取代来合成4-取代的7-氮杂吲哚衍生物。 -取代基。在本文中，我们报道了它们与酚盐和活化的亚甲基亲核试剂的反应。

  DOI：

  10.1016/j.tetlet.2006.01.143
• 作为产物：
  描述：

  4-氯-7-氮杂吲哚 在 甲基磺酰氯 、 间氯过氧苯甲酸 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 4,6-二氯-7-氮杂吲哚
  参考文献：
  名称：

  Synthesis of functionalized 7-azaindoles via directed ortho-metalations

  摘要：

  Functionalization at C-5 of 4-fluoro- and 4-chloro-1-triisopropylsilyl-7-azaindole, 1 and 2, respectively, leads to a variety of new substituted 7-azaindole derivatives. We also describe two approaches to introduce functionality at C-6. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.01.122

文献信息

• Highly Chemo- and Regioselective Vinylation of <i>N</i>-Heteroarenes with Vinylsulfonium Salts
  作者：Mingwei Zhou、Xuefei Tan、Yimin Hu、Hong C. Shen、Xuhong Qian

  DOI：10.1021/acs.joc.8b00682

  日期：2018.8.3

  An efficient chemo- and regioselective N-vinylation of N-heteroarenes has been developed using vinylsulfonium salts. The reaction proceeded under mild and transition-metal-free conditions and consistently provided moderate to high yields of vinylation products with 100% E-stereoselectivity. This reaction is also highly chemoselective, and compatible with a variety of functional groups, such as -NHR

  已经使用乙烯基ulf盐开发了N-杂芳烃的有效的化学和区域选择性N-乙烯基化。该反应在温和且无过渡金属的条件下进行，并始终以100％的E-立体选择性提供中等至高收率的乙烯基化产物。该反应也是高度化学选择性的，并且与多种官能团相容，例如-NHR，-NH 2，-OH，-COOH，酯等。
• [EN] HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
  申请人：ARTIOS PHARMA LTD

  公开号：WO2021028643A1

  公开（公告）日：2021-02-18

  The application relates to heterocyclic amide derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation. (Formula (I))

  该申请涉及杂环酰胺衍生物及其在癌症治疗和预防中的应用，以及含有这些衍生物的组合物和其制备方法。(化学式(I))
• [EN] THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE<br/>[FR] COMPOSITIONS THÉRAPEUTIQUEMENT ACTIVES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2012171337A1

  公开（公告）日：2012-12-20

  Provided are compounds with the following structure, formula (I) pharmaceutically acceptable salts thereof, use of those compounds for treating cancer and pharmaceutical compositions comprising those compounds.

  提供具有以下结构、式(I)的化合物，其药学上可接受的盐，以及利用这些化合物治疗癌症的用途和包含这些化合物的药物组合物。
• [EN] KINASE ANTAGONISTS AND METHODS FOR MAKING AND USING THEM<br/>[FR] ANTAGONISTES DES KINASES, PROCÉDÉS DE FABRICATION ET D'UTILISATION ASSOCIÉS
  申请人：BIOBLOCKS INC

  公开号：WO2020023393A1

  公开（公告）日：2020-01-30

  Disclosed herein are small molecule compounds that are SGK1 antagonists, formulations and pharmaceutical compositions comprising the compounds, and methods of making and using them, for treating, ameliorating, preventing, reversing or slowing the progression of: a cancer, a tumor, a metastasis or a dysplastic or a dysfunctional cell condition responsive to inhibition of a kinase enzyme of the AGC group of kinases including SGK1, by administration of an AGC kinase inhibitor or antagonist.

  本文披露了一种小分子化合物，它们是SGK1拮抗剂，包括这些化合物的配方和药物组合物，以及制备和使用它们的方法，用于治疗、改善、预防、逆转或减缓以下疾病的进展：癌症、肿瘤、转移瘤或对AGC激酶群中包括SGK1的激酶酶的抑制有反应的异型增生或功能异常细胞状况，通过给予AGC激酶抑制剂或拮抗剂。
• [EN] CD73 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE CD73 ET LEURS UTILISATIONS
  申请人：PELOTON THERAPEUTICS INC

  公开号：WO2018183635A1

  公开（公告）日：2018-10-04

  Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.

  本文描述了调节CD73活性的化合物、含有这些化合物的药物组合物，以及使用这些化合物治疗与CD73活性相关疾病的方法。